Theragenics Corporation  

(Public, NYSE:TGX)   Watch this stock  
Find more results for TGX
2.02
-0.02 (-0.98%)
Jun 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 2.02 - 2.06
52 week 1.32 - 2.15
Open 2.04
Vol / Avg. 48,235.00/121,210.00
Mkt cap 62.72M
P/E 31.78
Div/yield     -
EPS 0.06
Shares 31.05M
Beta 1.35
Inst. own 41%
Aug 5, 2013
Q2 2013 Theragenics Corporation Earnings Release Add to calendar
May 17, 2013
Theragenics Corporation Annual Shareholder Meeting
May 9, 2013
Q1 2013 Theragenics Corporation Earnings Conference Call - Webcast
May 9, 2013
Q1 2013 Theragenics Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -1.69% 2.59%
Operating margin -1.49% 4.56%
EBITD margin - 18.22%
Return on average assets -1.22% 1.93%
Return on average equity -1.68% 2.66%
Employees 534 -
Carbon Disclosure Rating - -

Address

5203 Bristol Industrial Way
BUFORD, GA 30518
United States - Map
+1-770-2710233 (Phone)
+1-770-8315294 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two business segments: surgical products segment and brachytherapy seed segment. The Company's surgical products business manufactures, markets and sells disposable devices primarily utilized in certain surgical procedures. The Company's brachytherapy seed business manufactures, markets and sells radioactive seeds primarily utilized in the treatment of early stage prostate cancer. The Company designs , manufacture, assemble, package and distributes its surgical products in three primary production facilities, each of which manufactures different products. The product lines in its surgical products business include Sutures, Elite HV Introducer Kits, Radial Artery Access Kits, Biopsy Needles, Orthopedic Needles, Pain Management Needles and Access Needles. On February 17, 2012, the Company acquired Core Oncology�s prostate brachytherapy customer base.

Officers and directors

M. Christine Jacobs Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Francis J. Tarallo Chief Financial Officer, Treasurer
Age: 52
Bio & Compensation  - Reuters
Joseph Plante President of NeedleTech Products
Age: 47
Bio & Compensation  - Reuters
Janet E. Zeman President of CP Medical
Age: 56
Bio & Compensation  - Reuters
Bruce W. Smith Executive Vice President - Strategy and Business Development, Secretary
Age: 59
Bio & Compensation  - Reuters
C. Russell Small Executive Vice President
Age: 52
Bio & Compensation  - Reuters
John V. Herndon Director
Age: 71
Bio & Compensation  - Reuters
Kathleen A. Dahlberg Independent Director
Age: 60
Bio & Compensation  - Reuters
K. Wyatt Engwall Independent Director
Age: 64
Bio & Compensation  - Reuters
Charles David Moody Jr. Independent Director
Age: 55
Bio & Compensation  - Reuters